EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Low Dose Methotrexate Has Divergent Effects on Cycling and Resting Human Hematopoietic Stem and Progenitor Cells

Maximilien Lora, H A Ménard, Anastasia Nijnik iD, David Langlais iD, Marie Hudson iD, Inés Colmegna iD

Clinical and Translational Science · 2025-05 · 18 (5)

DOI: 10.1111/cts.70233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 27.04.2025. Verfasst von Maximilien Lora und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada. Hauptthemen laut MEDLINE: Methotrexate, Hematopoietic Stem Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low dose methotrexate (LD‐MTX) remains the gold standard in rheumatoid arthritis (RA) therapy. Multiple mechanisms on a variety of immune cells contribute to the anti‐inflammatory effects of LD‐MTX. Inflammatory signaling is deeply implicated in hematopoiesis by regulating hematopoietic stem and progenitor cell (HSPC) fate decisions; raising the question of whether HSPC are also modulated by LD‐MTX. This is the first study to characterize the effects of LD‐MTX on HSPC. CD34 + HSPC were isolated from healthy donors' non‐mobilized peripheral blood. Resting and/or cycling HSPCs were treated with LD‐MTX [dose equivalent to that used in RA patients]. Flow cytometry was performed to assess HSPC viability, cell cycle, surface abundance of reduced folate carrier 1 (RFC1), proliferation, reactive oxygen species (ROS) levels, DNA double‐strand breaks, p38 activation, and CD34 + subpopulations. HSPC clonogenicity was tested in colony‐forming cell assays. Our results indicate that in cycling HSPC, membrane RFC1 is upregulated and, following LD‐MTX treatment, they accumulate more intracellular MTX than resting HSPC. In cycling HSPC, LD‐MTX inhibits HSPC expansion by promoting S‐phase cell‐cycle arrest, increases intracellular HSPC ROS levels and DNA damage, and reduces HSPC viability. Those effects involve the activation of the p38 MAPK pathway and are rescued by folinic acid. The effects of LD‐MTX are more evident in CD34 + CD38High progenitors. In non‐cycling HSPC, LD‐MTX also reduces the proliferative response while preserving their clonogenicity. In summary, HSPC uptake LD‐MTX differentially according to their cycling state. In turn, LD‐MTX results in reduced proliferation and the preservation of HSPC clonogenicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateHematopoietic Stem CellsHumansCell ProliferationReactive Oxygen SpeciesCells, CulturedCell CycleAntigens, CD34Cell SurvivalDose-Response Relationship, DrugReduced Folate Carrier ProteinArthritis, Rheumatoid

Stichwörter der Autor:innen

HSPCMTXarthritishematopoietic stem cellsmethotrexaterheumatoid

Substanzen

MethotrexateReactive Oxygen SpeciesAntigens, CD34Reduced Folate Carrier Protein

Autor:innen und Institutionen

  • The Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.
  • Professor Emeritus Division of Rheumatology, Department of Medicine, McGill University and RI-MUHC, Montreal, Canada.
  • Department of Physiology; McGill Research Centre on Complex Traits, McGill University, Montreal, Canada.
  • Research Centre on Complex Traits, Dahdaleh Institute of Genomic Medicine, Department of Human Genetics, Department of Microbiology and Immunology, McGill University, Montreal, Canada.
  • Division of Rheumatology, Department of Medicine, McGill University & Lady Davis Institute, Montreal, Canada.

ORCID-Profile: Anastasia Nijnik, David Langlais, Marie Hudson, Inés Colmegna

Zitieren

APA

Lora, M., Ménard, H. A., Nijnik, A., Langlais, D., Hudson, M., & Colmegna, I. (2025). Low Dose Methotrexate Has Divergent Effects on Cycling and Resting Human Hematopoietic Stem and Progenitor Cells. Clinical and Translational Science, 18(5). https://doi.org/10.1111/cts.70233

Vancouver

Lora M, Ménard HA, Nijnik A, Langlais D, Hudson M, Colmegna I. Low Dose Methotrexate Has Divergent Effects on Cycling and Resting Human Hematopoietic Stem and Progenitor Cells. Clinical and Translational Science. 2025;18(5). doi:10.1111/cts.70233

BibTeX
@article{Lora2025,
  author = {Lora, Maximilien and Ménard, H A and Nijnik, Anastasia and Langlais, David and Hudson, Marie and Colmegna, Inés},
  title = {Low Dose Methotrexate Has Divergent Effects on Cycling and Resting Human Hematopoietic Stem and Progenitor Cells},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {5},
  doi = {10.1111/cts.70233}
}
Kostenlos starten →